Pharmaceuticals
Zoetis Q2 2026 revenue was flat as U.S. companion animal declines offset international growth, while EPS rose slightly due to share repurchases.
Key risk: Tariffs and Trade Protection Measures
Uncertainty around U.S. tariffs and retaliatory actions could increase product costs and negatively impact demand. The company is monitoring the situation but the final applicability and effects remain unclear.
Other Pharmaceuticals companies